Yoshihisa Hagihara
Overview
Explore the profile of Yoshihisa Hagihara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
101
Citations
1324
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kibria M, Akazawa-Ogawa Y, Rahman N, Hagihara Y, Kuroda Y
Eur J Pharm Biopharm
. 2020 May;
152:164-174.
PMID: 32416134
Amorphous aggregates of therapeutic proteins can provoke an unwanted immune response (anti-drug antibodies; ADAs), but counter-examples have led to some controversy. Amorphous aggregates can possess unique biophysical and biochemical attributes...
12.
Akazawa-Ogawa Y, Komatsu Y, Nakajima Y, Kojima N, Hagihara Y
J Biochem
. 2020 Mar;
168(1):63-72.
PMID: 32154894
Site-specific conjugation of double-stranded DNA using antibodies enables the development of unique applications for antibody-drug conjugates utilizing recent advances in nucleic acid medicines. Here, we describe a novel method to...
13.
Shichiri M, Ishida N, Hagihara Y, Yoshida Y, Kume A, Suzuki H
J Clin Biochem Nutr
. 2019 Apr;
64(2):129-142.
PMID: 30936625
We previously reported that probucol, a lipid lowering agent, protected mice from malaria infection via depletion in plasma α-tocopherol. The antioxidant α-tocopherol in host circulation is necessary for the malaria...
14.
Nautiyal K, Kibria M, Akazawa-Ogawa Y, Hagihara Y, Kuroda Y
Biochem Biophys Res Commun
. 2018 Dec;
508(4):1043-1049.
PMID: 30551882
ScFv is emerging as a therapeutic alternative to the full-length monoclonal antibodies due to its small size and low production cost, but its low solubility remains a limiting factor toward...
15.
Noji M, So M, Yamaguchi K, Hojo H, Onda M, Akazawa-Ogawa Y, et al.
Biochemistry
. 2018 Aug;
57(37):5415-5426.
PMID: 30148614
Although ovalbumin (OVA), a main component of hen egg white and a non-inhibitory serpin superfamily protein, has been reported to form fibrillar aggregates, its relationship with amyloid fibrils associated with...
16.
Suzuki T, Mochizuki Y, Kimura S, Akazawa-Ogawa Y, Hagihara Y, Nemoto N
Biochem Biophys Res Commun
. 2018 Aug;
503(3):2054-2060.
PMID: 30119893
Single-domain antibodies (variable domain of the heavy chain of a heavy chain antibody; VHH) are promising reagents for therapeutics and diagnostics because of their stability, cost-effective production and material workability...
17.
Umeno A, Fukui T, Hashimoto Y, Kataoka M, Hagihara Y, Nagai H, et al.
J Clin Biochem Nutr
. 2018 Apr;
62(2):187-194.
PMID: 29610560
We previously reported that type 2 diabetes risk, early impaired glucose tolerance and insulin resistance can be predicted by measuring the fasting levels of certain biomarkers. Here we validated these...
18.
Furutani S, Nishio K, Naruishi N, Akazawa-Ogawa Y, Hagihara Y, Yoshida Y, et al.
Anal Sci
. 2018 Mar;
34(3):379-382.
PMID: 29526909
We have developed a compact disc (CD)-shaped microfluidic device for multiple, rapid enzyme-linked immunosorbent assays (ELISA). The device has a versatile design that can be adapted for the detection of...
19.
Akazawa-Ogawa Y, Nagai H, Hagihara Y
Biophys Rev
. 2017 Dec;
10(2):255-258.
PMID: 29256117
The antibody is one of the most well-studied multi-domain proteins because of its abundance and physiological importance. In this article, we describe the effect of the complex, multi-domain structure of...
20.
Fukui H, Iwahashi H, Nishio K, Hagihara Y, Yoshida Y, Horie M
Toxicol Ind Health
. 2017 Sep;
33(9):687-695.
PMID: 28854869
Exposure to zinc oxide nanoparticles (ZnO NPs) promotes acute pulmonary toxicity through oxidative stress and inflammation. Furthermore, dissolved zinc from ZnO NPs induces the formation of intracellular reactive oxygen species...